Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-121445
Filing Date
2024-11-05
Accepted
2024-11-05 16:05:21
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q stok-20240930.htm   iXBRL 10-Q 1938033
2 EX-31.1 stok-ex31_1.htm EX-31.1 16202
3 EX-31.2 stok-ex31_2.htm EX-31.2 16012
4 EX-32.1 stok-ex32_1.htm EX-32.1 8104
5 EX-32.2 stok-ex32_2.htm EX-32.2 8886
  Complete submission text file 0000950170-24-121445.txt   6209106

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20240930.xsd EX-101.SCH 735996
61 EXTRACTED XBRL INSTANCE DOCUMENT stok-20240930_htm.xml XML 885236
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 241427417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)